<DOC>
	<DOCNO>NCT01683825</DOCNO>
	<brief_summary>The primary aim pilot study determine whether amyloid deposit heart measure non-invasively F-18 florbetapir ( Trade Name : Amyvid ) positron emission tomography ( PET ) 30 individual document cardiac amyloidosis . We also enroll 15 individual without cardiac amyloidosis undergo F-18 florbetapir image control group . The primary hypothesis study specific amyloid binding radiotracer bind myocardial amyloid deposit help quantify cardiac amyloid burden . A secondary aim study determine reproducibility F-18 florbetapir image myocardium .</brief_summary>
	<brief_title>Imaging Cardiac Amyloidosis : A Pilot Study Using F-18 Florbetapir Positron Emission Tomography</brief_title>
	<detailed_description>F-18 florbetapir study multiple clinical trial image beta-amyloid deposition brain subject Alzheimers ' disease . Florbetapir F-18 well tolerate study 2000 human subject . Biodistribution study human reveal predominantly hepatobiliary excretion . The tracer clear rapidly blood pool 20 minute . This radiotracer recently approve clinical image brain amyloid subject suspect Alzheimers disease . The investigator propose test FDA approve radiotracer label indication pilot study evaluate potential utility , , image cardiac amyloidosis . Amyloid related heart disease associate LV wall thicken due infiltration ; however , myocardial wall thicken definitively distinguishable leave ventricular myocyte hypertrophy increase afterload heart hypertension aortic stenosis . Typically myocardial tissue biopsy typical echo feature amyloidosis require confirmation amyloidosis . This pilot study design understand whether cardiac amyloid burden measure use specific radiotracer target amyloid protein ( F-18 Florbetapir ) . At point unknown F-18 Florbetapir bind either AL TTR amyloid protein neither . The investigator would like study 15 patient AL 15 patient TTR amyloidosis understand difference . The investigator also seek understand signal noise ratio circulate amyloid protein blood pool ( AL amyloid disease ) allow good differentiation myocardial amyloid uptake . 15 individual without cardiac amyloidosis also enrol control study . The purpose propose research study examine detail , use quantitative PET , myocardial F-18 Florbetapir uptake cardiac amyloidosis order well understand mechanism heart damage disease . A secondary aim study determine reproducibility F-18 florbetapir image myocardium .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Inclusion criterion amyloid subject : Age &gt; 18 year Biopsy proven amyloidosis outside heart typical echocardiographic appearance cardiac involvement , positive cardiac biopsy . Diagnosis AL amyloidosis standard criterion ( evidence plasma cell dyscrasia appropriate tissue stain AL ) OR Diagnosis TTR amyloidosis ( evidence plasma call dyscrasia positive TTR stain amyloid tissue biopsy ) Able willing provide inform consent participate study procedure Pregnancy Serious noncardiac medical illness preclude research study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Amyloidosis</keyword>
	<keyword>Cardiac</keyword>
	<keyword>Heart</keyword>
	<keyword>Imaging</keyword>
	<keyword>Diagnosis</keyword>
</DOC>